SEC Form 4 · accession 0001140361-18-030103
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 25, 2018 | C | 1,745,974 | — | A | 1,745,974 | I | See footnote |
| Common StockF2 | Jun 25, 2018 | P | 666,668 | $15.00 | A | 2,412,642 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Convertible Preferred StockF2,F1 | — | Jun 25, 2018 | C | 3,109,796 | D | — | — | Common Stock | 1,745,974 | 0 | I |
Explanation of responses
- F1The Series C Convertible Preferred Stock converted into shares of the Issuer's common stock on a 1.78112-for-1 basis and had no expiration date.
- F2These securities are directly owned by certain private investment vehicles and separately managed accounts managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.